Looking for an alternative to Mounjaro? Here is what is actually licensed in the UK

The myth worth clearing up first: Ozempic is not a weight-loss alternative

A large share of people searching for alternatives to Mounjaro have Ozempic in mind. Ozempic is semaglutide (the same active ingredient as Wegovy) but its UK licence covers type 2 diabetes management, not weight loss. Prescribing it for weight loss would be off-label, and the MHRA has been clear that GLP-1 medicines are not assessed for cosmetic or quick weight-loss use. Rybelsus, the oral diabetes tablet that also contains semaglutide, sits in the same category. If you have seen either name on social media as a Mounjaro alternative, the correct UK weight-loss version is Wegovy, available as an injection pen or, since June 2026, as a daily tablet.

The same goes for Saxenda (liraglutide), which is licensed for weight management but is an older GLP-1 medicine with a different dosing schedule and a different evidence profile. It remains on the UK market; it is simply not dispensed by nume.

Worth checking in under a minute: if you find a seller offering Ozempic or Rybelsus specifically as a weight-loss treatment, look up the pharmacy on the GPhC register. An unregistered seller offering prescription medicines is a red flag the MHRA has warned about repeatedly.

How Wegovy injection compares to Mounjaro as a direct alternative

Wegovy (semaglutide 2.4mg, made by Novo Nordisk) was the dominant injectable weight-loss medicine in the UK before Mounjaro arrived. In the STEP 1 trial, participants lost an average of around 15% of their body weight over 68 weeks, a meaningful result by any historical standard. Mounjaro's SURMOUNT-1 trial reported closer to 20–21% average loss at the highest dose over 72 weeks. The head-to-head data from SURMOUNT-5, published in the New England Journal of Medicine in 2025, confirmed that tirzepatide produced greater average weight reduction than semaglutide 2.4mg, the difference being real and statistically meaningful, not just noise between trials.

That said, the 2024 approval of a 7.2mg Wegovy dose (a single-dose pen was confirmed by the MHRA on 14 April 2026) narrows the gap: the 7.2mg trial reported around 20.7% average weight loss over 72 weeks, approaching tirzepatide 15mg results. So for someone who cannot tolerate Mounjaro or who has a clinical reason to use a GLP-1-only medicine, the higher-dose Wegovy injection is a credible alternative, not a consolation prize. NICE recommends Wegovy under TA875 for eligible adults, though NHS access requires a specialist weight management service.

Side-effect profiles overlap considerably, nausea, diarrhoea, constipation and indigestion are the most frequently reported effects with both. Oral contraceptive absorption may be reduced specifically with tirzepatide; there is no equivalent evidence for semaglutide, which is a practical distinction some women factor into the choice.

The Wegovy tablet: a genuinely new alternative for people who prefer not to inject

For many people the barrier to treatment is not efficacy but the injection itself. The Wegovy tablet addresses that directly. The MHRA approved it on 11 June 2026, the first oral GLP-1 medicine licensed for weight management in the UK, and the UK was the first country in Europe to grant that approval. It contains oral semaglutide with an absorption enhancer and is taken once daily, first thing in the morning, before food, drink or other medicines.

The phase 3 OASIS 4 trial (307 adults with obesity or overweight plus at least one weight-related condition, over 64 weeks) found an average weight loss of around 13.6% versus 2.4% for placebo. Among participants who stayed fully adherent to treatment the figure was closer to 17%. The trade-off against injection is modest: slightly lower average results, but no needle, no refrigeration, and a simpler travelling routine. More detail on the tablet option covers the dosing schedule and what to expect in the first weeks.

For a broader comparison of all the licensed options side by side, this overview of Mounjaro alternatives for weight loss sets out the evidence in one place. And if your question is specifically about whether an alternative to Mounjaro exists that suits your specific situation, that page goes into the clinical factors that a prescriber weighs up.

Orlistat and the broader picture

Orlistat is the other UK-licensed weight-management medicine and works entirely differently: it blocks around a third of dietary fat from being absorbed, rather than acting on appetite hormones. It has been available for decades, is available in lower doses without a prescription from a pharmacy, and suits some people well, particularly those who want to avoid injectable medicines and for whom the Wegovy tablet is not appropriate. Average weight loss is lower than with GLP-1 medicines. The NHS orlistat page covers side effects (principally GI, and closely tied to fat intake) clearly.

The honest picture is that no single medicine is right for everyone. Mechanism, tolerance, lifestyle, other medications and health history all shape which option a prescriber recommends, and this guide to what's the alternative to Mounjaro is worth reading if you want a plain-English walkthrough of how those factors are weighed up. If you want to understand Mounjaro itself before comparing, or explore the full range of treatments nume offers, both pages are worth reading first. People sometimes also wonder how easy it is to get Mounjaro, and that page walks through the eligibility criteria and what the process involves. Weight loss treatment options gives a plain-English map of what exists and how each fits different starting points.

When you are ready, speaking to our prescribers is the practical next step, a free consultation, reviewed the same day by a real clinician, with no commitment until treatment is confirmed as appropriate for you. Start your free consultation.